Standard
Arterial stiffness and atrial fibrillation recurrence : another risk marker or a call for better management of concomitant disease? / de Groot, J. R.; Linz, D.
In:
Netherlands Heart Journal, Vol. 30, No. 4, 2022, p. 187-189.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
de Groot, JR
& Linz, D 2022, '
Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease?',
Netherlands Heart Journal, vol. 30, no. 4, pp. 187-189.
https://doi.org/10.1007/s12471-022-01678-8APA
de Groot, J. R.
, & Linz, D. (2022).
Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease? Netherlands Heart Journal,
30(4), 187-189.
https://doi.org/10.1007/s12471-022-01678-8Vancouver
de Groot JR
, Linz D.
Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease? Netherlands Heart Journal. 2022;30(4):187-189.
https://doi.org/10.1007/s12471-022-01678-8Author
de Groot, J. R. ; Linz, D. / Arterial stiffness and atrial fibrillation recurrence : another risk marker or a call for better management of concomitant disease?. In: Netherlands Heart Journal. 2022 ; Vol. 30, No. 4. pp. 187-189.
Bibtex
@article{3c103f95505d4c5395794fc9c627885f,
title = "Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease?",
author = "{de Groot}, {J. R.} and D. Linz",
note = "Funding Information: J.R. de Groot has received research grants through his institution from Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson & Johnson and Medtronic, and honoraria/speaker{\textquoteright}s fees from AtriCure, Bayer, BIOTRONIK, CardioVasculair Onderwijs Instituut, Daiichi Sankyo, Medtronic, Novartis and Servier. D. Linz has received research grants through his institution from Bayer and Biosense Webster, and honoraria/speaker{\textquoteright}s fees from Daiichi Sankyo, Medtronic, BIOTRONIK, Respicardia and Itamar Medical.",
year = "2022",
doi = "10.1007/s12471-022-01678-8",
language = "English",
volume = "30",
pages = "187--189",
journal = "Netherlands Heart Journal",
issn = "1568-5888",
publisher = "Bohn Stafleu van Loghum",
number = "4",
}
RIS
TY - JOUR
T1 - Arterial stiffness and atrial fibrillation recurrence
T2 - another risk marker or a call for better management of concomitant disease?
AU - de Groot, J. R.
AU - Linz, D.
N1 - Funding Information:
J.R. de Groot has received research grants through his institution from Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson & Johnson and Medtronic, and honoraria/speaker’s fees from AtriCure, Bayer, BIOTRONIK, CardioVasculair Onderwijs Instituut, Daiichi Sankyo, Medtronic, Novartis and Servier. D. Linz has received research grants through his institution from Bayer and Biosense Webster, and honoraria/speaker’s fees from Daiichi Sankyo, Medtronic, BIOTRONIK, Respicardia and Itamar Medical.
PY - 2022
Y1 - 2022
UR - http://www.scopus.com/inward/record.url?scp=85126100330&partnerID=8YFLogxK
U2 - 10.1007/s12471-022-01678-8
DO - 10.1007/s12471-022-01678-8
M3 - Journal article
C2 - 35258798
AN - SCOPUS:85126100330
VL - 30
SP - 187
EP - 189
JO - Netherlands Heart Journal
JF - Netherlands Heart Journal
SN - 1568-5888
IS - 4
ER -
